SecBot SecBot

ENTX

Entera Bio Ltd.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. L3· CIK 0001638097 Biotech & Drug Discovery
$2.86 −0.06 (−2.05%)
Oct 26 4:00 PM ET · prev $2.92
Market cap
$525.2M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$9.50
+232% · range $9.00–11.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.07
1 year
+22.7%
from $2.33 · Oct 27
30 days
+6.3%
from $2.69
52-week range
$1.00–3.92
−27% from high · low Mar 30
Avg volume 20D
674.7K
shares / day
Short interest
2.40M
≈1.4% of shares · +87.5%
Days to cover
5.2
at average volume
Insider net
+$101.5K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 6 reports · 90 days
Balance 0 bearish · 0 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 5, 2026
Strongest MIXED Entera Bio is holding a special shareholder meeting on November 24, 2026, to vote on eight proposals tied to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $101.5K at an average $1.34. No open-market sales. Price is 113% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.080 → −$0.068 over 90 days.

  • Short sellersBUILDING

    Short interest +87.5% to 2.40M shares. 5.2 days to cover, ≈1.4% of shares.

  • TrendDOWNTREND

    1% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
PNC FINANCIAL SERVICES GROUP, INC.DOUBLED273,031$483.3K
HighTower Advisors, LLCDOUBLED74,573$132.9K
HRT FINANCIAL LPDOUBLED72,486$128.0K
CITADEL ADVISORS LLCNEAR_EXIT38,804$68.7K
JPMORGAN CHASE & CODOUBLED40,883$67.5K
GEODE CAPITAL MANAGEMENT, LLCADD29,908$52.9K
JANE STREET GROUP, LLCTRIM17,331$30.7K
UBS Group AGDOUBLED12,723$22.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +232%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 25, 2026Guggenheim
INITIATE
INITIATEBuy
Sep 23, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Sep 22, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Sep 18, 2026Leerink Partners
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$101.5K
bought · 3 insiders
$0
sold · 0 insiders
+112.7%
vs their $1.34 cost
DateInsiderTypeValue
Aug 7, 2026
Ellis Sean
Director
AWARD40,000 sh
Aug 7, 2026
Taitel Haya
Director
AWARD20,790 sh
Aug 7, 2026
Malca Yonatan
Director
AWARD22,815 sh
Aug 7, 2026
Yaacov-Garbeli Dana
Chief Financial Officer
AWARD140,000 sh
Aug 7, 2026
Rubin Steven D
Director
AWARD33,368 sh
Aug 7, 2026
Toledano Miranda Jayne
Chief Executive Officer
AWARD500,000 sh
Aug 7, 2026
Galitzer Hillel
Chief Operating Officer
AWARD200,000 sh
Aug 7, 2026
Rubin Steven D
Director
AWARD19,117 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.07
EPS estimate, this quarter
+15%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.07-$0.09–-$0.05+15.0%$0.00
Next Q-$0.14-$0.21–-$0.05-53.3%$0.00
Current FY-$0.40-$0.52–-$0.25-18.2%$0.00
Next FY-$0.42-$0.57–-$0.35+26.3%$0.00

Short side

FINRA· Sep 30, 2026
2,403,597
shares short
+87.5%
vs prior settlement
5.2
days to cover
≈1.4%
of shares outstanding
Trading halts
Jul 27, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Entera Bio is holding a special shareholder meeting on November 24, 2026, to vote on eight proposals tied to its $275…
DEF 14A — Impact 6/10
Oct 6, 2026 SEC
Entera Bio appointed former Gilead and Amgen executive Laura Hamill to its Board of Directors, effective December 1…
8-K — Impact 3/10
Sep 30, 2026 Short interest report
Short Interest: ENTX up 88% to 2.4M shares
Settlement 2026-09-30 | Days to cover: 5.18 | ≈1.38% of shares outstanding (est.)
Aug 27, 2026 Press
Entera Bio announced that CEO Miranda Toledano will present at three upcoming investor conferences (Cantor…
Impact 2/10
Aug 18, 2026 SEC
Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, effective immediately, to lead late-stage…
8-K — Impact 3/10
Aug 7, 2026 Insider
Ellis Sean was granted 40,000 shares
Director
Aug 7, 2026 Insider
Taitel Haya was granted 20,790 shares
Director
Aug 7, 2026 Insider
Malca Yonatan was granted 22,815 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
ENTX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 30, 2026
Short interest
Short Interest: ENTX up 88% to 2.4M shares
Settlement 2026-09-30 | Days to cover: 5.18 | ≈1.38% of shares outstanding (est.)
Aug 27, 2026
Announcement
Correction: Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral…
Aug 7, 2026
Earnings
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet…
Aug 7, 2026
Earnings date
ENTX Q2 2026 Earnings Scheduled — 2026-08-07
Aug 6, 2026
Earnings date
ENTX Q2 2026 Earnings Scheduled — 2026-08-06

SecBot reports

9 filings · 7 press releases · 0 bullish · 1 bearish · 2 mixed · 6 neutral
All ENTX filing & press-release reports (16)